Anna Karjalainen

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

Vappu Rantalaiho, Markku Korpela, Leena Laasonen et al. · Arthritis Research & Therapy · 2010 · 106 citations · Full text

Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma.

A. Hirvonen, K. Pelin, L. Tammilehto et al. · PubMed · 1995 · 96 citations

Gstm1 Gene, Epidemiology Of Cancer, Human Polymorphism +17

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

Marjatta Leirisalo‐Repo, Hannu Kautiainen, Leena Laasonen et al. · Annals of the Rheumatic Diseases · 2012 · 96 citations

Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study

Kari Palosaari, J. Vuotila, R. Takalo et al. · Lara D. Veeken · 2006 · 96 citations · Full text